The GLUCARE consortium, which Safe Implant Technology is part of, has secured a prestigious Eurostars funding to execute the groundbreaking GLUCARE project. Selected among 506 competing consortiums globally, GLUCARE has a budget of ~€1.3 million.
The Market Opportunity
The GLUCARE consortium aims to address a pressing market need — the development of a first-of-its-kind, long-term implantable biosensor for continuous glucose monitoring (CGM). With 463 million diabetic patients spending approximately €3000 per year on CGM devices, the market is vast. Current solutions fall short due to short operational life, frequent surgical interventions, high costs, and safety concerns.
The GLUCARE Solution
Our project centers on the development of a CGM biosensor with an innovative surface coating, GP5. This coating is a game-changer, significantly reducing adverse reactions and extending subcutaneous residency time beyond 2 years. The ultimate goal is to deliver a fully developed prototype, tested in animal models, and poised for clinical validation.
Key Innovations
- Longevity: Overcoming the 180-day limitation of existing biosensors, GLUCARE offers a long-term solution.
- Innovative Coating (GP5): Reducing adverse reactions and improving subcutaneous residency time, GP5 enhances patient safety and comfort.
- Cost-Effectiveness: By minimizing the need for frequent replacements and surgical interventions, GLUCARE is positioned as a cost-effective solution for patients.
- Reliability and Accuracy: Ensuring continuous reliability and accuracy, GLUCARE addresses the shortcomings of current CGM devices.
Beyond GLUCARE
Safe Implant Technology, holding the patent for GP5, seeks investment not only to drive the GLUCARE project but also to expand GP5 into other MedTech areas relevant for implantable medical devices.
Integrating Predictive Biomarkers and AI
In addition to GLUCARE, our vision extends to predictive biomarkers and AI-driven solutions. By monitoring patient needs through predictive biomarkers, we aim to optimize medical administration based on biosensor feedback. Simultaneously, we recognize the resource constraints faced by healthcare staff, particularly MDs and nurses. To bridge this gap, AI will play a pivotal role in streamlining processes, enhancing efficiency, and ultimately improving patient outcomes.